Semax 5 mg

What it is

Semax is a synthetic peptide analogue of a fragment of adrenocorticotropic hormone, developed and registered in Russia for certain indications. It is not registered in South Africa or most other markets.

Mechanism being studied

Research describes possible effects on BDNF expression and monoaminergic signalling in animal models.

Human evidence

Most clinical literature originates from a small number of research groups and is not widely replicated to contemporary international trial standards. Evidence should be considered insufficient for general conclusions.

Safety considerations

Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.

Regulatory status

Registration status varies substantially by country. In South Africa it is not a registered medicine. Confirm locally before any professional consideration.

Certificate of analysis

Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.

Key references

• Peer-reviewed neuroscience literature indexed under 'Semax'.
• National medicines registers for country-specific status.

References are provided as reading directions for professionals. They do not constitute endorsement of any use.